Overview

Press Releases & News

Stay informed on the latest breakthroughs, partnerships, and milestones at PGxAI. Our press releases and news updates reflect our ongoing commitment to transforming healthcare through AI-powered precision medicine.
News
PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Drugs Including Ozempic®
photo
Date
Apr 23, 2025
Summary
PGxAI has released an AI-driven genetic report that tailors GLP-1 therapies—including semaglutide brands Ozempic® and Wegovy®—to each patient’s genome, flagging high-risk variants and delivering actionable dosing or alternative-drug guidance within minutes via EHR integration.
Highlights
Identifies risk variants in up to ⅓ of semaglutide patients
Covers 10+ GLP-1, dual-incretin, and CNS-based weight-loss drugs
Real-time decision support through InterSystems HealthShare
News
PGxAI Debuts Deneb, an AI Model Revolutionizing Drug Development for Biopharma
photo
Date
Apr 15, 2025
Summary
PGxAI has launched Deneb, an AI pharmacogenetics model for biopharma and CROs that fuses molecular, physicochemical, and genomic data to deliver real-time PGx guidance, cutting trial costs and speeding drugs to market.
Highlights
Real-time PGx insights for cohort, dose, safety
Automates multi-omics + structure data; shortens trials
Powered by NVIDIA, Microsoft, InterSystems stack
News
PGxAI Debuts Vega, an AI Model Set to Disrupt Precision Medicine
photo
Date
Feb 28, 2025
Summary
PGxAI has unveiled Vega, an AI-powered pharmacogenetics model that instantly converts a patient’s genomic data into drug-specific treatment recommendations, covering 1,200 drugs and 350 genes—vastly surpassing traditional panels.
Highlights
1,200 drugs / 350 genes analyzed in minutes
Cuts adverse-reaction risk via automated guideline interpretation
Built with GenAI; integrates into EHRs through InterSystems HealthShare
Press Release
Revolutionizing Precision Medicine: PGxAI Raises $1.5 Million in Funding for AI-Powered Pharmacogenetics Platform
photo
Date
Dec 24, 2024
Summary
PGxAI has raised $1.5 million to scale its AI-powered pharmacogenetics platform, funding upgrades to its VectorSearch and GenAI tools and deepening its partnership with InterSystems to deliver ultra-precise, genome-guided prescribing.
Highlights
$1.5M round accelerates tech development
Boosts VectorSearch & GenAI for dose, drug-selection, DDI insights
Leverages InterSystems’ vast patient data to sharpen precision medicine
News
The Ventures Award: The World's Premier Stage for Startup Excellence
photo
Date
Dec 21, 2024
Summary
PGxAI captured the top prize at The Ventures Award—Silicon Valley’s roaming startup showcase—outshining hundreds of global contenders with its AI-powered pharmacogenomics platform. The tour now heads to Chicago on 7 Feb 2025 before expanding to other tech hubs worldwide.
Highlights
PGxAI wins flagship Ventures Award
30-city, 19-country pitch circuit
Next event: Chicago, 7 Feb 2025
Press Release
PGxAI Launches Sirius, an AI‑Powered Pharmacogenetics Model
photo
Date
Dec 19, 2024
Summary
PGxAI has launched Sirius, an AI-driven pharmacogenetics model that tailors drug choice, dosage, and interaction management to each patient’s genome, enabling ultra-precision prescribing for hospitals, labs, and CROs.
Highlights
Covers 730 drugs and 40 key pharmacogenes—more than twice the scope of typical solutions—aiming to avert up to 30% of adverse drug reactions.
Leverages partnerships with Nvidia, Microsoft, Google, Meta, AWS, and InterSystems, integrating seamlessly into EHR workflows via HealthShare.
Ambitious roadmap: expand to 1 700 drugs in 2025, add GenAI and federated-learning upgrades by 2026, and harness >1 billion real-world outcomes by 2030.
Press Release
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration
photo
Date
Jun 25, 2024
Summary
BioStrand (ImmunoPrecise) and PGxAI are partnering to build an AI-driven pharmacogenomics model on BioStrand’s LENSai platform to deliver personalized drug-response predictions and speed up LENSai API adoption.
Highlights
Integrates LENSai’s multi-omics AI with PGxAI’s real-world genomic data to forecast efficacy, dose, and safety.
Aims to cut the >30% rate of drug-related adverse events and improve precision prescribing.
Targets the $400B prescription market, unlocking new revenue as the LENSai API scales.
Stay Connected
Looking ahead, our mission remains unwavering
Stay informed on the latest breakthroughs, partnerships, and milestones at PGxAI. Our press releases and news updates reflect our ongoing commitment to transforming healthcare through AI-powered precision medicine.
integration icon
Email Updates
Subscribe to our newsletter for monthly insights, product launches, and upcoming events.
integration icon
LinkedIn
Follow PGxAI for real-time updates on industry trends and company announcements.
integration icon
Media Inquiries
For press and media relations, email admin@pgx.ai or call +1 (415) 246-5322.
Get in Touch
Ready to Shape the Future of Precision Medicine?
PGxAI continues to evolve with each development, furthering our mission to deliver personalized care that benefits patients, providers, and all stakeholders in the healthcare ecosystem.
Email Us: admin@pgxai.com
Schedule a Demo